OptiBiotix Health plc (AIM: OPTI) – further contract signed with NIZO Food Research
We reported on OptiBiotix last week, it is a very exciting new business operating in one of the most progressive areas of biotechnological research. It aims to develop compounds which modify the human microbiome to help combat obesity, diabetes and high cholesterol.
Using its technology platforms for microbiome modulation, the Group has generated three research programmes which they are developing in the functional foods and health supplements marketplace.
Previous article Next article